Results 231 to 240 of about 203,803 (267)
Some of the next articles are maybe not open access.
Gériatrie et Psychologie Neuropsychiatrie du Viellissement, 2011
The incidence of malignant gliomas is growing in the elderly population. Unfortunately, increasing age is one of the most important negative prognostic factors for gliomas, and the optimal management of this population remains largely unsettled because older patients are often excluded from clinical trials.
Florence, Laigle-Donadey +1 more
openaire +2 more sources
The incidence of malignant gliomas is growing in the elderly population. Unfortunately, increasing age is one of the most important negative prognostic factors for gliomas, and the optimal management of this population remains largely unsettled because older patients are often excluded from clinical trials.
Florence, Laigle-Donadey +1 more
openaire +2 more sources
Critical Reviews in Oncology/Hematology, 2008
Glioblastoma (GBM) is the most malignant among astrocytic tumours and is associated with a poor prognosis. Age, performance status, mini-mental status examination score, methylation status of methylguanine methyltransferase promoter and extent of surgery constitute the main prognostic factors.
Brandes AA +5 more
openaire +3 more sources
Glioblastoma (GBM) is the most malignant among astrocytic tumours and is associated with a poor prognosis. Age, performance status, mini-mental status examination score, methylation status of methylguanine methyltransferase promoter and extent of surgery constitute the main prognostic factors.
Brandes AA +5 more
openaire +3 more sources
Journal of Clinical Oncology, 2017
Glioblastoma (GBM) is a rare tumor and one of the most challenging malignancies to treat in all of oncology. Although advances have been made in the treatment of GBM, encouraging outcomes typically are not observed; patients diagnosed with these tumors generally have a dismal prognosis and poor quality of life as the disease progresses.
Brian M, Alexander, Timothy F, Cloughesy
openaire +2 more sources
Glioblastoma (GBM) is a rare tumor and one of the most challenging malignancies to treat in all of oncology. Although advances have been made in the treatment of GBM, encouraging outcomes typically are not observed; patients diagnosed with these tumors generally have a dismal prognosis and poor quality of life as the disease progresses.
Brian M, Alexander, Timothy F, Cloughesy
openaire +2 more sources
Current Treatment Options in Neurology, 2009
Optimal management of newly diagnosed glioblastoma multiforme includes maximal surgical resection, followed by 60 Gy of external beam radiation plus concomitant daily temozolomide and at least six additional monthly cycles of maintenance temozolomide.
Mary, Welch, Rose, Lai
openaire +2 more sources
Optimal management of newly diagnosed glioblastoma multiforme includes maximal surgical resection, followed by 60 Gy of external beam radiation plus concomitant daily temozolomide and at least six additional monthly cycles of maintenance temozolomide.
Mary, Welch, Rose, Lai
openaire +2 more sources
Immunotherapies continue to hold promise for the treatment of glioblastoma, a malignant central nervous system tumor. Thus far, success utilizing this approach has been limited. Negative trials with vaccines and immune checkpoint inhibitors have been unable to demonstrate improvement in survival, however, they have provided insights into hurdles which ...
Andrew, Williams, Rimas V, Lukas
openaire +2 more sources
Andrew, Williams, Rimas V, Lukas
openaire +2 more sources
Current Treatment Options in Neurology, 2008
Patients with newly diagnosed glioblastoma multiforme should undergo a maximal tumor resection and then, whenever possible, should be entered into a clinical trial. The current standard of care consists of external beam irradiation, to a total of 60 Gy over 6 weeks, in combination with low-dose daily temozolomide, followed by at least six cycles of ...
openaire +2 more sources
Patients with newly diagnosed glioblastoma multiforme should undergo a maximal tumor resection and then, whenever possible, should be entered into a clinical trial. The current standard of care consists of external beam irradiation, to a total of 60 Gy over 6 weeks, in combination with low-dose daily temozolomide, followed by at least six cycles of ...
openaire +2 more sources
2014
There is no generally agreed upon standard of care treatment for elderly patients (age ≥70 years) with glioblastoma (GBM). Treatment options range from supportive care only, radiation therapy (RT) only (most often given in a shortened hypofractionated schedule), temozolomide (TMZ) chemotherapy only, and the combination RT + TMZ, followed by post-RT TMZ
openaire +2 more sources
There is no generally agreed upon standard of care treatment for elderly patients (age ≥70 years) with glioblastoma (GBM). Treatment options range from supportive care only, radiation therapy (RT) only (most often given in a shortened hypofractionated schedule), temozolomide (TMZ) chemotherapy only, and the combination RT + TMZ, followed by post-RT TMZ
openaire +2 more sources
Neurosurgery, 1980
The accumulated retrospective experience with glioblastoma multiforme was reviewed. Data were extracted from 17 reports in the literature, comprising 2532 patients. Survival curves were constructed for 1561 selected cases that did not include limited surgery and/or astrocytoma Grade III.
openaire +2 more sources
The accumulated retrospective experience with glioblastoma multiforme was reviewed. Data were extracted from 17 reports in the literature, comprising 2532 patients. Survival curves were constructed for 1561 selected cases that did not include limited surgery and/or astrocytoma Grade III.
openaire +2 more sources